We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Tag: PCI
MedXY News
EnglishTag

PCI

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Determining the Physiological Threshold for Angina (ORBITA-FIRE): A Double-Blind, Randomized, Placebo-Controlled Study
CardiologyanginaCardiology

Determining the Physiological Threshold for Angina (ORBITA-FIRE): A Double-Blind, Randomized, Placebo-Controlled Study

By MedXY|Jun 10, 2026

ORBITA-FIRE shows that angina occurs at much lower, individualized FFR and RFR thresholds than standard ischemia cutoffs, and these thresholds rise with exercise intensity.

Women with Chronic Coronary Artery Disease: Long-Term Outcomes After PCI vs CABG
Cardiologycoronary artery diseasePCI
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story

Women with Chronic Coronary Artery Disease: Long-Term Outcomes After PCI vs CABG

By MedXY|Aug 18, 2026

In women with chronic severe coronary artery disease, CABG was linked to lower long-term rates of death, stroke, heart attack, repeat revascularization, and cardiovascular readmission than PCI.

Evolocumab in Patients With Prior Percutaneous Coronary Intervention and No Prior MI: Results From the VESALIUS-CV Trial
Cardiologycoronary artery diseaseEvolocumab

Evolocumab in Patients With Prior Percutaneous Coronary Intervention and No Prior MI: Results From the VESALIUS-CV Trial

By MedXY|May 19, 2026

In patients with prior PCI but no prior MI, evolocumab significantly lowered LDL-C and reduced major cardiovascular events, including myocardial infarction and urgent revascularization, supporting intensive lipid lowering after coronary int

Determining the Physiological Threshold for Angina (ORBITA-FIRE): A Double-Blind, Randomized, Placebo-Controlled Study
CardiologyanginaFFR

Determining the Physiological Threshold for Angina (ORBITA-FIRE): A Double-Blind, Randomized, Placebo-Controlled Study

By MedXY|May 9, 2026

ORBITA-FIRE study reveals personalized physiological thresholds for angina that are lower than current diagnostic standards. These thresholds vary during exercise and predict PCI treatment success, challenging universal ischemia-based guide

Ticagrelor Falls Short: TUXEDO-2 Trial Challenges Antiplatelet Choice in Diabetic Patients With Multivessel Disease
CardiologydiabetesMultivessel Coronary Artery Disease

Ticagrelor Falls Short: TUXEDO-2 Trial Challenges Antiplatelet Choice in Diabetic Patients With Multivessel Disease

By MedXY|Apr 13, 2026

The TUXEDO-2 trial reveals that ticagrelor did not meet noninferiority criteria compared with prasugrel in diabetic patients with multivessel coronary artery disease undergoing PCI. At 1 year, the primary composite endpoint of death, MI, st

IVUS Guidance Slashes 1-Year Target Vessel Failure in Complex Bifurcation PCI: Insights from DKCRUSH VIII
CardiologyCardiologyDK Crush

IVUS Guidance Slashes 1-Year Target Vessel Failure in Complex Bifurcation PCI: Insights from DKCRUSH VIII

By MedXY|Mar 31, 2026

The DKCRUSH VIII trial demonstrates that IVUS-guided PCI for complex coronary bifurcation lesions significantly reduces 1-year target vessel failure compared to angiography guidance, primarily by ensuring adherence to specific optimization

Percutaneous Coronary Intervention Before TAVR: A Nationwide Synthesis of Clinical Outcomes and Bleeding Risks
Cardiologyclinical trialscoronary artery disease

Percutaneous Coronary Intervention Before TAVR: A Nationwide Synthesis of Clinical Outcomes and Bleeding Risks

By MedXY|Mar 2, 2026

A nationwide Swedish registry analysis demonstrates that routine PCI before TAVR for significant coronary artery disease does not improve survival or reduce urgent revascularization, but significantly increases bleeding risk while reducing

Is Prasugrel the New Gold Standard? Ticagrelor Fails Noninferiority in High-Risk Diabetic and STEMI Populations
Cardiologydiabetesmyocardial infarction

Is Prasugrel the New Gold Standard? Ticagrelor Fails Noninferiority in High-Risk Diabetic and STEMI Populations

By MedXY|Feb 20, 2026

Recent data from the TUXEDO-2 and ISAR-REACT 5 trials suggest prasugrel may provide superior outcomes over ticagrelor in high-risk PCI patients, including those with diabetes and STEMI.

FFR-Guided PCI Demonstrates Decade-Long Superiority Over Medical Therapy in Stable Coronary Artery Disease
CardiologyFractional Flow ReservePCI

FFR-Guided PCI Demonstrates Decade-Long Superiority Over Medical Therapy in Stable Coronary Artery Disease

By MedXY|Feb 4, 2026

An 11-year follow-up of the FAME 2 trial reveals that FFR-guided PCI significantly outperforms medical therapy alone in patients with hemodynamically significant stenoses, primarily by reducing urgent revascularizations, with a favorable wi

Abluminus DES+ Fails to Achieve Non-Inferiority Against XIENCE EES in Patients with Diabetes: Results from the ABILITY Diabetes Global Trial
Cardiologycoronary artery diseaseDiabetes Mellitus

Abluminus DES+ Fails to Achieve Non-Inferiority Against XIENCE EES in Patients with Diabetes: Results from the ABILITY Diabetes Global Trial

By MedXY|Jan 18, 2026

The ABILITY Diabetes Global trial demonstrates that the Abluminus DES+ sirolimus-eluting stent failed to meet non-inferiority compared to the XIENCE everolimus-eluting stent in patients with diabetes, showing significantly higher rates of t

Validating the 0.80 FFR Threshold: Long-Term Outcomes from the NOTION-3 Trial in TAVR Patients
Cardiologycoronary artery diseaseFractional Flow Reserve

Validating the 0.80 FFR Threshold: Long-Term Outcomes from the NOTION-3 Trial in TAVR Patients

By MedXY|Jan 17, 2026

The NOTION-3 trial demonstrates that FFR-guided revascularization significantly reduces cardiovascular risks in TAVR patients with coronary artery disease, validating the 0.80 threshold for clinical decision-making.

Moving Beyond the 12-Month Default: Personalized DAPT Duration Proven Superior in the PARTHENOPE Trial
CardiologyAntithrombotic TherapyCardiology

Moving Beyond the 12-Month Default: Personalized DAPT Duration Proven Superior in the PARTHENOPE Trial

By MedXY|Jan 17, 2026

The PARTHENOPE randomized trial demonstrates that personalizing DAPT duration (3 to 24 months) based on individual risk scores significantly reduces net adverse clinical events compared to standard 12-month therapy, primarily by lowering is

Baseline Risk Does Not Resuscitate PCI Benefit in Ischemic Cardiomyopathy: Lessons from the REVIVED-BCIS2 Sub-analysis
Cardiologyheart failureIschemic Cardiomyopathy

Baseline Risk Does Not Resuscitate PCI Benefit in Ischemic Cardiomyopathy: Lessons from the REVIVED-BCIS2 Sub-analysis

By MedXY|Jan 3, 2026

A prespecified analysis of the REVIVED-BCIS2 trial reveals that baseline risk of death or hospitalization does not modify the effectiveness of PCI in patients with ischemic left ventricular dysfunction, reinforcing the primacy of optimal me

FFR-Guided Revascularization Significantly Reduces 12-Month MACCE in TAVI Patients: The FAITAVI Trial
CardiologyFFRPCI

FFR-Guided Revascularization Significantly Reduces 12-Month MACCE in TAVI Patients: The FAITAVI Trial

By MedXY|Jan 3, 2026

The FAITAVI trial demonstrates that physiology-guided PCI using FFR significantly reduces major adverse cardiac events, particularly mortality, compared to angiography-guided PCI in elderly patients undergoing TAVI with intermediate coronar

Timing Matters: Platelet Reactivity Predicts Early Events While Clinical Risk Governs Long-Term Outcomes Post-PCI
CardiologyCardiologyPCI

Timing Matters: Platelet Reactivity Predicts Early Events While Clinical Risk Governs Long-Term Outcomes Post-PCI

By MedXY|Dec 30, 2025

Analysis of the PTRG-DES registry shows that platelet reactivity drives early ischemic risk post-PCI, while clinical risk factors (TRS2P) determine long-term prognosis, suggesting a need for temporally tailored secondary prevention strategi

Refining Risk: Clinical and Angiographic Predictors of Postprocedural Troponin Elevation in Elective PCI
CardiologyCardiologymyocardial infarction

Refining Risk: Clinical and Angiographic Predictors of Postprocedural Troponin Elevation in Elective PCI

By MedXY|Dec 30, 2025

A comprehensive analysis of over 10,000 patients identifies key risk factors for post-PCI troponin increase, highlighting the protective role of intravascular imaging and the prognostic impact of different myocardial infarction definitions.

Early Aspirin Withdrawal After PCI in ACS: Less Bleeding but Not Clearly Safe — Lessons from the NEO-MINDSET Trial
CardiologyPCI

Early Aspirin Withdrawal After PCI in ACS: Less Bleeding but Not Clearly Safe — Lessons from the NEO-MINDSET Trial

By MedXY|Dec 6, 2025

In patients with acute coronary syndromes treated with PCI, stopping aspirin within 4 days and continuing potent P2Y12 inhibitor monotherapy reduced bleeding but did not meet noninferiority for ischemic events versus 12‑month DAPT; stent th

Stopping Aspirin After 1 Month Post‑PCI in Low‑Risk AMI: P2Y12 Monotherapy Is Noninferior and Bleeding‑Sparing
Cardiologyacute myocardial infarctionDual Antiplatelet Therapy

Stopping Aspirin After 1 Month Post‑PCI in Low‑Risk AMI: P2Y12 Monotherapy Is Noninferior and Bleeding‑Sparing

By MedXY|Dec 6, 2025

In low‑risk AMI patients with early complete revascularization and uneventful 1‑month DAPT, P2Y12‑inhibitor monotherapy was noninferior to continued DAPT for ischemic outcomes and substantially reduced clinically relevant bleeding.

Early Aspirin Withdrawal after PCI in Low‑Risk MI: P2Y12‑Inhibitor Monotherapy Noninferior and Significantly Less Bleeding
Cardiologyacute myocardial infarctionPCI

Early Aspirin Withdrawal after PCI in Low‑Risk MI: P2Y12‑Inhibitor Monotherapy Noninferior and Significantly Less Bleeding

By MedXY|Dec 6, 2025

In low‑risk acute MI patients with early complete revascularization and 1 month of uneventful DAPT, stopping aspirin and continuing P2Y12‑inhibitor monotherapy was noninferior for ischemic outcomes and cut clinically relevant bleeding nearl

CABG Provides Superior Long-Term Outcomes to PCI in Women with Chronic Severe CAD: Real‑World Ontario Cohort Shows Lower MACCE and Mortality
CardiologyCABGcoronary artery disease

CABG Provides Superior Long-Term Outcomes to PCI in Women with Chronic Severe CAD: Real‑World Ontario Cohort Shows Lower MACCE and Mortality

By MedXY|Nov 28, 2025

In a propensity‑matched Ontario cohort of women with chronic severe coronary artery disease, CABG was associated with lower long‑term MACCE and all‑cause mortality than PCI over a median 5.1 years.

1 / 2
12
Next
Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities